

10/583,468

STM-Structure Search
1/11/08

=> d ibib abs hitstr 1-3

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:15873 CAPLUS

DOCUMENT NUMBER: 144:108216

TITLE: Preparation of amido compounds as inhibitors of
11- β -hydroxysteroid dehydrogenase type 1
(11 β HSD1) and antagonists of the
mineralocorticoid receptor (MR)

INVENTOR(S): Yao, Wenqing; Xu, Meizhong; Zhang, Colin; Agrios,
Konstantinos; Metcalf, Brian; Zhuo, Jincong

PATENT ASSIGNEE(S): Incyte Corporation, USA

SOURCE: PCT Int. Appl., 108 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2006002349	A1	20060105	WO 2005-US22411	20050623
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005258248	A1	20060105	AU 2005-258248	20050623
CA 2571258	A1	20060105	CA 2005-2571258	20050623
US 2006009471	A1	20060112	US 2005-159724	20050623
EP 1758582	A1	20070307	EP 2005-762543	20050623
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1988908	A	20070627	CN 2005-80020965	20050623
IN 2006KN03601	A	20070615	IN 2006-KN3601	20061201
KR 2007024639	A	20070302	KR 2006-727142	20061222
NO 2007000372	A	20070308	NO 2007-372	20070119
PRIORITY APPLN. INFO.:			US 2004-582556P	P 20040624
			US 2004-639179P	P 20041222
			WO 2005-US22411	W 20050623
OTHER SOURCE(S):		MARPAT 144:108216		
GI				



AB The title compds. I [Cy = (un)substituted (hetero)aryl, (hetero)cycloalkyl; L = absent, (CR13R14)m, (CR13R14)nO(CR13R14)p, etc.; R1, R2 = (un)substituted alkyl; R3-R12 = H, W1X1Y1Z1; or R3 and R4 together or R5 and R6 together or R7 and R8 together or R9 and R10 together or R11 and R12 together form 4-20 membered cycloalkyl or (un)substituted heterocycloalkyl; or R3 and R12 together or R3 and R10 together or R3 and R8 together or R5 and R10 together or R5 and R10 together or R7 and R12 together form (un)substituted alkylene bridge; R13, R14 = H, halo, alkyl, etc.; W1 = absent, alkylenyl, O, etc.; X1 = absent, alkylenyl, aryl, etc.; Y1 = absent, O, S, etc.; Z1 = H, halo, CN, etc.; m = 1-4; n = 0-3; p = 0-3; q = 0-2; with the provisos] which are inhibitors of 11- β hydroxysteroid dehydrogenase type 1 and antagonists of the mineralocorticoid receptor (MR), were prepared Thus, reacting 2-(4-chlorophenyl)-2-methylpropanoic acid with (1S)-1,2,3,4-tetrahydroisoquinolin-1-ylmethanol in the presence of BOP and N-methylmorpholine in DMF afforded (1S)-II. The compds. I can be useful in the treatment of various diseases associated with expression or activity of 11- β hydroxysteroid dehydrogenase type 1 and/or diseases associated with aldosterone excess. The pharmaceutical composition comprising the compound

I is disclosed.

IT 872985-55-2P 872986-34-0P 872986-36-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(preparation of amido compds. as inhibitors of 11- β -hydroxysteroid dehydrogenase type 1 (11 β HSD1) and antagonists of the mineralocorticoid receptor (MR))

RN 872985-55-2 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-[2-(4-chlorophenoxy)-2-methyl-1-oxopropyl]-, (1'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/583,468



RN 872986-34-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[1,1-dimethyl-2-oxo-2-[(1R)-3-oxospiro[isobenzofuran-1(3H), 3'-pyrrolidin]-1'-yl]ethoxy]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 872986-36-2 CAPLUS

CN Spiro[isobenzofuran-1(3H), 3'-pyrrolidin]-3-one, 1'-[2-methyl-1-oxo-2-[4-(1-piperazinyl)phenoxy]propyl]-, (1R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 872985-48-3P 872985-49-4P 872985-50-7P
872985-51-8P 872985-52-9P 872985-53-0P
872985-54-1P 872985-56-3P 872985-57-4P
872986-15-7P 872986-19-1P 872986-21-5P
872986-23-7P 872986-25-9P 872986-27-1P
872986-38-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU


10/583,468

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amido compds. as inhibitors of 11- β -hydroxysteroid dehydrogenase type 1 (11 β HSD1) and antagonists of the mineralocorticoid receptor (MR))


RN 872985-48-3 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-[2-(4-cyanophenoxy)-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 872985-49-4 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-[2-(4-chlorophenoxy)-2-methyl-1-oxopropyl]- (CA INDEX NAME)




RN 872985-50-7 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-[2-[4-(cyanomethyl)phenoxy]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 872985-51-8 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidine], 1'-[2-[4-(cyanomethyl)phenoxy]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 872985-52-9 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-[2-methyl-1-oxo-2-[4-(2-pyridinyl)phenoxy]propyl]- (CA INDEX NAME)




RN 872985-53-0 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-[2-[(4'-fluoro[1,1'-biphenyl]-4-yl)oxy]-2-methyl-1-oxopropyl]- (CA INDEX NAME)



RN 872985-54-1 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidine], 1'-[2-[(4'-fluoro[1,1'-biphenyl]-4-yl)oxy]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 872985-56-3 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-[2-(2,4-dichlorophenoxy)-2-methyl-1-oxopropyl]-, (1'R)- (9CI) (CA INDEX NAME)

10/583,468


Absolute stereochemistry.



RN 872985-57-4 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-[2-(3,4-dichlorophenoxy)-2-methyl-1-oxopropyl]-, (1'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872986-15-7 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-(2-methyl-1-oxo-2-phenoxypropyl)-, (1R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 872986-19-1 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-[2-(3,5-dichlorophenoxy)-2-methyl-1-oxopropyl]-, (1R)- (CA INDEX NAME)

Absolute stereochemistry.


10/583,468



RN 872986-21-5 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-[2-[4-chloro-3-(trifluoromethyl)phenoxy]-2-methyl-1-oxopropyl]-, (1R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 872986-23-7 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-[2-(4-chloro-3-fluorophenoxy)-2-methyl-1-oxopropyl]-, (1R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 872986-25-9 CAPLUS


CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-[2-(4-chloro-2-methylphenoxy)-2-methyl-1-oxopropyl]-, (1R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 872986-27-1 CAPLUS
CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-[2-methyl-1-oxo-2-[4-(trifluoromethyl)phenoxy]propyl]-, (1R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 872986-38-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-[1,1-dimethyl-2-oxo-2-[(1R)-3-oxospiro[isobenzofuran-1(3H),3'-pyrrolidin]-1'-yl]ethoxy]phenyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:588965 CAPLUS
DOCUMENT NUMBER: 143:115452
TITLE: Preparation of tricyclic spiropiperidines as

10/583,468

modulators of chemokine receptor activity
INVENTOR(S): Hossain, Nafizal; Ivanova, Svetlana
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061499	A1	20050707	WO 2004-SE1938	20041220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004303735	A1	20050707	AU 2004-303735	20041220
AU 2004303735	B2	20070920		
CA 2548494	A1	20050707	CA 2004-2548494	20041220
EP 1699791	A1	20060913	EP 2004-809111	20041220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
BR 2004017036	A	20070206	BR 2004-17036	20041220
CN 1918160	A	20070221	CN 2004-80042013	20041220
JP 2007515476	T	20070614	JP 2006-546906	20041220
MX 2006PA07025	A	20060831	MX 2006-PA7025	20060619
US 2007099945	A1	20070503	US 2006-583468	20060620
IN 2006MN00848	A	20070518	IN 2006-MN848	20060718
NO 2006003355	A	20060922	NO 2006-3355	20060719
PRIORITY APPLN. INFO.:			SE 2003-3541	A 20031222
			WO 2004-SE1938	W 20041220
OTHER SOURCE(S):			CASREACT 143:115452; MARPAT 143:115452	
GI				



AB Title compds. I [$m = 0-4$; $R_1 = \text{halo, CN, OH, etc.}$; $X = \text{bond, CH}_2$ and $Y = \text{bond, CH}_2$ provided that X, Y do not both simultaneously represent bond, CH_2 ; $n = 0-2$; $R_2 = \text{halo, alkyl, haloalkyl}$; $q = 0-1$; $p = 0-2$; $R_3 = \text{halo, amino, carboxyl, etc.}$; $R_4 = \text{H, alkyl, haloalkyl, halo}$; $a = 0-2$ provided that p and a are not both 0; $R_5 = (\text{un})\text{saturated } 5-10\text{-membered ring system}$] are prepared For instance, II is prepared in 4 steps from 5-methoxy-2-nitrophenol, (S)-oxiran-2-ylmethanol, and 5-chlorospiro[3H-benzofuran-2,4'-piperidine] (preparation given). I are modulators of chemokine receptor activity [no data] and useful for the treatment of, e.g., rheumatoid arthritis.


IT 857264-51-8P, N-[2-[3-Amino-2-(spiro[3H-benzofuran-2,4'-piperidin]-1'-yl)propoxy]-4-methoxyphenyl]acetamide

RL: BYP (Byproduct); PREP (Preparation)

(preparation of tricyclic spiropiperidines as modulators of chemokine receptor activity)

RN 857264-51-8 CAPLUS

CN Acetamide, N-[2-(3-amino-2-spiro[benzofuran-2(3H),4'-piperidin]-1'-yl)propoxy]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)



IT 857264-43-8P, N-[2-[[3-Amino-2-(5-chlorospiro[3H-benzofuran-2,4'-piperidin]-1'-yl)propyl]oxy]-4-methoxyphenyl]acetamide


RL: BYP (Byproduct); SPN (Synthetic preparation); PREP (Preparation)

(preparation of tricyclic spiropiperidines as modulators of chemokine receptor activity)


RN 857264-43-8 CAPLUS

CN Acetamide, N-[2-[3-amino-2-(5-chlorospiro[benzofuran-2(3H),4'-piperidin]-1'-yl)propoxy]-4-methoxyphenyl]- (CA INDEX NAME)


10/583,468



IT 857264-79-0P, 5-Chloro-2-[2-chloro-3-(5-chlorospiro[3H-benzofuran-2,4'-piperidin]-1'-yl)propoxy]-4-[(4-methoxybenzyl)oxy]benzoic acid trifluoroacetate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tricyclic spiropiperidines as modulators of chemokine receptor activity)
RN 857264-79-0 CAPLUS
CN Benzoic acid, 5-chloro-2-[2-chloro-3-(5-chlorospiro[benzofuran-2(3H),4'-piperidin]-1'-yl)propoxy]-4-[(4-methoxyphenyl)methoxy]-, trifluoroacetate (9CI) (CA INDEX NAME)
CM 1
CRN 857264-78-9
CMF C30 H30 Cl3 N O6



CM 2
CRN 76-05-1
CMF C2 H F3 O2





REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:41477 CAPLUS
DOCUMENT NUMBER: 140:93937
TITLE: Preparation of tricyclic spiropiperidines or spiropyrrolidines useful against disorders affected by modulation of chemokine receptors
INVENTOR(S): Hossain, Nafizal; Ivanova, Svetlana; Mensonides-Harsema, Marguerite
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 281 pp.

CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004005295	A1	20040115	WO 2003-SE1185	20030707
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492122	A1	20040115	CA 2003-2492122	20030707
AU 2003243122	A1	20040123	AU 2003-243122	20030707
EP 1521757	A1	20050413	EP 2003-762957	20030707
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003012560	A	20050510	BR 2003-12560	20030707
CN 1675218	A	20050928	CN 2003-819146	20030707
JP 2005537255	T	20051208	JP 2004-519472	20030707
NZ 537259	A	20060831	NZ 2003-537259	20030707
CN 1974574	A	20070606	CN 2006-10143556	20030707
IN 2004DN04014	A	20070427	IN 2004-DN4014	20041216
ZA 2005000024	A	20060222	ZA 2005-24	20050103
MX 2005PA00278	A	20050331	MX 2005-PA278	20050104
US 2005245741	A1	20051103	US 2005-520699	20050107
NO 2005000635	A	20050331	NO 2005-635	20050204
PRIORITY APPLN. INFO.:			SE 2002-2133	A 20020708
			CN 2003-819146	A3 20030707
			WO 2003-SE1185	W 20030707

OTHER SOURCE(S): MARPAT 140:93937
 GI



AB The invention provides tricyclic spiropiperidines or spiropyrrolidines (shown as I; variables defined below; e.g. II), processes for their preparation, pharmaceutical compns. containing them and their use in therapy for

disorders affected by modulation of chemokine receptors (no data). For I: m is 0-4; each R1 = halogen, cyano, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or sulfonamido; either X = a bond, -CH2-, -O- or -C(O)- and Y = a bond, -CH2-, -O- or -C(O)-, or X and Y together = -CH:CMe- or -CMe:CH-, and Z = a bond, -O-, -NH- or -CH2-, provided that only one of X, Y and Z can be a bond at any one time and provided that X and Y do not both simultaneously = -O- or -C(O)-. N = 0-2; each R2 = halogen or C1-C6 alkyl; q = 0-1; R3 = -NHC(O)R10, -C(O)NR11R12 or -COOR12a; R4, R5, R6, R7 and R8 = H or a C1-C6 alkyl group; t = 0-2; each R9 = halogen, cyano, hydroxy, carboxy, C1-C6 alkoxy, C1-C6 alkoxycarbonyl, C1-C6 haloalkyl, or C1-C6 alkyl; addnl. details are given in the claims. Methods of preparation are claimed and >200 example preps. are included. For example, II was prepared in 2 steps starting from N-(2-hydroxyphenyl)acetamide, ((2S)-oxiran-2-yl)methyl and Cs2CO3 in DMF to give N-[2-(((2S)-oxiran-2-yl)methoxy)phenyl]acetamide as an intermediate, which was reacted with 5-chloro-3H-spiro[1-benzofuran-2,4'-piperidine] in EtOH to give II.

IT 644968-87-6P 644969-01-7P 644969-11-9P

644969-20-0P 644969-46-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of tricyclic spiropiperidines or spiropyrrolidines useful against disorders affected by modulation of chemokine receptors)

RN 644968-87-6 CAPLUS


CN Acetamide, N-[2-[(2S)-3-(5-chlorospiro[benzofuran-2(3H),4'-piperidin]-1'-yl)-2-hydroxy-2-methylpropoxy]-4-hydroxyphenyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 644968-86-5

CMF C24 H29 Cl N2 O5


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




10/583,468

RN 644969-01-7 CAPLUS

CN Acetamide, N-[2-[(2S)-2-hydroxy-2-methyl-3-spiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl]propoxy]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 644969-11-9 CAPLUS

CN Benzamide, 2-[(2S)-3-(5-chlorospiro[benzofuran-2(3H),4'-piperidin]-1'-yl)-2-hydroxy-2-methylpropoxy]-N-cyclopropyl-4-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 644969-20-0 CAPLUS

CN Benzamide, 2-[(2S)-3-(5-chlorospiro[benzofuran-2(3H),4'-piperidin]-1'-yl)-2-hydroxy-2-methylpropoxy]-4-hydroxy-N-methyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 644969-19-7

CMF C24 H29 Cl N2 O5

Absolute stereochemistry.


10/583,468



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 644969-46-0 CAPLUS

CN Benzamide, 2-[(2S)-3-(5-chlorospiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl)-2-hydroxy-2-methylpropoxy]-N-cyclopropyl-4-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.



IT 644969-14-2P 644969-23-3P 644969-47-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of tricyclic spiropiperidines or spiropyrrolidines useful against disorders affected by modulation of chemokine receptors)

RN 644969-14-2 CAPLUS

CN Benzamide, 2-[(2S)-3-(5-chlorospiro[benzofuran-2(3H),4'-piperidin]-1'-yl)-2-hydroxy-2-methylpropoxy]-N-cyclopropyl-4-[(4-methoxyphenyl)methoxy]- (CA INDEX NAME)

10/583,468


Absolute stereochemistry.



RN 644969-23-3 CAPLUS

CN Benzamide, 2-[(2S)-3-(5-chlorospiro[benzofuran-2(3H),4'-piperidin]-1'-yl)-2-hydroxy-2-methylpropoxy]-4-[(4-methoxyphenyl)methoxy]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 644969-47-1 CAPLUS

CN Benzamide, 2-[(2S)-3-(5-chlorospiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl)-2-hydroxy-2-methylpropoxy]-N-cyclopropyl-4-[(4-methoxyphenyl)methoxy]- (CA INDEX NAME)

Absolute stereochemistry.

10/583,468



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 11:43:59 ON 11 JAN 2008)

FILE 'REGISTRY' ENTERED AT 11:44:10 ON 11 JAN 2008

L1 STRUCTURE UPLOADED

L2 2 S L1

L3 65 S L1 FULL


FILE 'CAPLUS' ENTERED AT 11:45:10 ON 11 JAN 2008

L4 3 S L3

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,N,X

Structure attributes must be viewed using STN Express query preparation.

=>